With the availability of numerous FLT3 inhibitors, what may still be unanswered is the order of sequence in using type 1, and 2 FLT3 inhibitors in de novo and R/R FLT3ITD‐mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.